Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Braz. j. med. biol. res ; 45(9): 841-850, Sept. 2012. ilus
Artículo en Inglés | LILACS | ID: lil-646329

RESUMEN

The combined treatment with histone deacetylase inhibitors (HDACi) and retinoids has been suggested as a potential epigenetic strategy for the control of cancer. In the present study, we investigated the effects of treatment with butyrate, a dietary HDACi, combined with vitamin A on MCF-7 human breast cancer cells. Cell proliferation was evaluated by the crystal violet staining method. MCF-7 cells were plated at 5 x 10(4) cells/mL and treated with butyrate (1 mM) alone or combined with vitamin A (10 µM) for 24 to 120 h. Cell proliferation inhibition was 34, 10 and 46% following treatment with butyrate, vitamin A and their combination, respectively, suggesting that vitamin A potentiated the inhibitory activities of butyrate. Furthermore, exposure to this short-chain fatty acid increased the level of histone H3K9 acetylation by 9.5-fold (Western blot), but not of H4K16, and increased the expression levels of p21WAF1 by 2.7-fold (Western blot) and of RARβ by 2.0-fold (quantitative real-time PCR). Our data show that RARβ may represent a molecular target for butyrate in breast cancer cells. Due to its effectiveness as a dietary HDACi, butyrate should be considered for use in combinatorial strategies with more active retinoids, especially in breast cancers in which RARβ is epigenetically altered.


Asunto(s)
Femenino , Humanos , Anticarcinógenos/farmacología , Neoplasias de la Mama/patología , Butiratos/farmacología , Proliferación Celular/efectos de los fármacos , Metilación de ADN/efectos de los fármacos , Inhibidores de Histona Desacetilasas/farmacología , Vitamina A/farmacología , Anticarcinógenos/administración & dosificación , Butiratos/administración & dosificación , Inhibidores de Histona Desacetilasas/administración & dosificación , Vitamina A/administración & dosificación
2.
Braz. j. med. biol. res ; 44(6): 538-545, June 2011. ilus
Artículo en Inglés | LILACS | ID: lil-589976

RESUMEN

β-ionone (βI), a cyclic isoprenoid, and geraniol (GO), an acyclic monoterpene, represent a promising class of dietary chemopreventive agents against cancer, whose combination could result in synergistic anticarcinogenic effects. The chemopreventive activities of βI and GO were evaluated individually or in combination during colon carcinogenesis induced by dimethylhydrazine in 48 3-week-old male Wistar rats (12 per group) weighing 40-50 g. Animals were treated for 9 consecutive weeks with βI (16 mg/100 g body weight), GO (25 mg/100 g body weight), βI combined with GO or corn oil (control). Number of total aberrant crypt foci (ACF) and of ACF ≥4 crypts in the distal colon was significantly lower in the GO group (66 ± 13 and 9 ± 2, respectively) compared to control (102 ± 9 and 17 ± 3) and without differences in the βI (91 ± 11 and 14 ± 3) and βI+GO groups (96 ± 5 and 19 ± 2). Apoptosis level, identified by classical apoptosis morphological criteria, in the distal colon was significantly higher in the GO group (1.64 ± 0.06 apoptotic cells/mm²) compared to control (0.91 ± 0.07 apoptotic cells/mm²). The GO group presented a 0.7-fold reduction in Bcl-2 protein expression (Western blot) compared to control. Colonic mucosa concentrations of βI and GO (gas chromatography/mass spectrometry) were higher in the βI and GO groups, respectively, compared to the control and βI+GO groups. Therefore, GO, but not βI, represents a potential chemopreventive agent in colon carcrvpdate=20110329inogenesis. Surprisingly, the combination of isoprenoids does not represent an efficient chemopreventive strategy.


Asunto(s)
Animales , Masculino , Ratas , Anticarcinógenos/uso terapéutico , Neoplasias del Colon/prevención & control , Norisoprenoides/uso terapéutico , Terpenos/uso terapéutico , Anticarcinógenos/farmacocinética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinógenos , Colon/metabolismo , Neoplasias del Colon/inducido químicamente , Neoplasias del Colon/metabolismo , Dimetilhidrazinas , Ensayos de Selección de Medicamentos Antitumorales/métodos , Mucosa Intestinal/metabolismo , Norisoprenoides/farmacocinética , Ratas Wistar , Terpenos/farmacocinética
3.
Braz. j. med. biol. res ; 43(3): 242-248, Mar. 2010. graf, tab
Artículo en Inglés | LILACS | ID: lil-539721

RESUMEN

The chemopreventive potential of water extracts of the Brassica vegetables cabbage and kale was evaluated by administering their aqueous extracts in drinking water ad libitum to Wistar rats submitted to Ito’s hepatocarcinogenesis model (CB group and K group, respectively - 14 rats per group). Animals submitted to this same model and treated with water were used as controls (W group - 15 rats). Treatment with the vegetable extracts did not inhibit (P > 0.05) placental glutathione S-transferase-positive preneoplastic lesions (PNL). The number of apoptotic bodies did not differ (P > 0.05) among the experimental groups. Ex vivo hydrogen peroxide treatment of rat livers resulted in lower (P < 0.05) DNA strand breakage in cabbage- (107.6 ± 7.8 µm) and kale- (110.8 ± 10.0 µm) treated animals compared with control (120.9 ± 12.7 µm), as evaluated by the single cell gel (comet) assay. Treatment with cabbage (2 ± 0.3 µg/g) or kale (4 ± 0.2 µg/g) resulted in increased (P < 0.05) hepatic lutein concentration compared with control (0.5 ± 0.07 µg/g). Despite the absence of inhibitory effects of cabbage and kale aqueous extracts on PNL, these Brassica vegetables presented protection against DNA damage, an effect possibly related to increased hepatic lutein concentrations. However, it must be pointed out that the cause-effect relationship between lutein levels and protection is hypothetical and remains to be demonstrated.


Asunto(s)
Animales , Masculino , Ratas , Antioxidantes/farmacología , Brassica/química , Daño del ADN , Neoplasias Hepáticas Experimentales/prevención & control , Extractos Vegetales/farmacología , Lesiones Precancerosas/prevención & control , Anticarcinógenos/farmacología , Apoptosis/efectos de los fármacos , ADN , Glutatión Transferasa/análisis , Neoplasias Hepáticas Experimentales/inducido químicamente , Neoplasias Hepáticas Experimentales/enzimología , Lesiones Precancerosas/inducido químicamente , Lesiones Precancerosas/enzimología , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA